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Ablation of Enpp6 Results in Transient Bone
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1The Roslin Institute and Royal (Dick) School of Veterinary Studies, University of Edinburgh, Midlothian, UK
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ABSTRACT
Biomineralization is a fundamental process key to the development of the skeleton. The phosphatase orphan phosphatase 1 (PHOS-
PHO1), which likely functions within extracellular matrix vesicles, has emerged as a critical regulator of biomineralization. However,
the biochemical pathways that generate intravesicular PHOSPHO1 substrates are currently unknown. We hypothesized that the
enzyme ectonucleotide pyrophosphatase/phosphodiesterase 6 (ENPP6) is an upstream source of the PHOSPHO1 substrate. To test
this, we characterized skeletal phenotypes of mice homozygous for a targeted deletion of Enpp6 (Enpp6−/−). Micro-computed tomog-
raphy of the trabecular compartment revealed transient hypomineralization in Enpp6−/− tibias (p < 0.05) that normalized by
12 weeks of age. Whole-bone cortical analysis also revealed significantly hypomineralized proximal bone in 4- but not 12-week-
old Enpp6−/−mice (p < 0.05) compared with WT animals. Back-scattered SEM revealed a failure in 4-week-old trabecular bone of min-
eralization foci to propagate. Static histomorphometry revealed increased osteoid volume (p > 0.01) and osteoid surface (p < 0.05),
which recovered by 12 weeks but was not accompanied by changes in osteoblast or osteoclast number. This study is the first to char-
acterize the skeletal phenotype of Enpp6−/− mice, revealing transient hypomineralization in young animals compared with WT con-
trols. These data suggest that ENPP6 is important for bonemineralization andmay function upstream of PHOSPHO1 as a novel means
of generating its substrates inside matrix vesicles. © 2020 The Authors. JBMR Plus published by Wiley Periodicals LLC. on behalf of
American Society for Bone and Mineral Research.
KEY WORDS: ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 6; MATRIX MINERALIZATION; MATRIX VESICLE; ORPHAN PHOSPHATASE
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Introduction
Biomineralization of the skeleton is a fundamental processindispensable for health and well-being throughout life.
The vertebrate skeleton is a hugely complex organ that performs
varied and diverse functions encompassing its action as a biome-
chanical and protective scaffold in conjunction with the muscu-
lature, its role in calcium (Ca2+) ion and inorganic phosphate (Pi)
homeostasis, and recent evidence demonstrating its capacity as
an endocrine organ involved with energy homeostasis.(1) Matrix
vesicles (MVs) are membrane-bound nanospherical bodies
100 to 300 nm in diameter, which are associated with both phys-
iological and pathological biomineralization.(2,3) Many in vitro
and in vivo studies have shown the first mineral crystals in
diverse mineralized tissues, such as bone, dentin, and cartilage,
are affiliated with these vesicles in the extracellular matrix.(4-6)
MVs are hypothesized to facilitate regulated biomineralization
through provision of a locally protected environment within
which Ca2+ and Pi may accumulate in an amorphous state but
that also enable transport and targeting of cargo to the pre-
formed collagenous matrix.
The biochemical mechanisms through which Pi is generated
within MVs are currently unclear. Orphan phosphatase 1 (PHOS-
PHO1; Phospho1) was identified as a novel bone phosphatase
critical for mineralization.(7-9) The PHOSPHO1 KO mouse (Phos-
pho1−/−) displays a hypomineralized skeleton at birth, biome-
chanical incompetency, scoliosis, and spontaneous greenstick
fractures.(10,11) A key observation was the capacity of PHOSPHO1
to generate Pi, with specific activity towards phosphocholine
(PCho) and phosphoethanolamine (PEA).(12-14) Although we
and others have validated the presence of biologically active
PHOSPHO1 within MVs,(13,15) how PEA and PCho are generated
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within the vesicles for hydrolysis by PHOSPHO1 is as yet
unknown.
The current leading model for intravesicular PHOSPHO1 func-
tion involves the chemical transformation of vesicle membrane
constituent phospholipids into appropriate enzymatic substrates
for PHOSPHO1.(3,16) An as-yet unidentified enzyme (or group of
enzymes) with phospholipase A2 activity is first hypothesized
to convert membrane-constituent phosphatidylcholine to lyso-
phosphatidylcholine.(9,16) Several vertebrate PLA2 isoforms are
known to be expressed by chondrocytes and osteoblasts and
were localized to actively mineralizing matrix in cartilage and
metaphyseal bone.(17,18) However, specific candidates that may
function as part of the MV mechanism have yet to be identified.
Ectonucleotide pyrophosphatase/phosphodiesterase 6 (ENPP6;
or glycerophosphocholine cholinephosphodiesterase) is a mem-
ber of the nucleotide pyrophosphatase/phosphodiesterase fam-
ily with lysophospholipase C activity, catalyzing the conversion
of lysophosphatidylcholine to PCho with a monoacylglycerol
byproduct.(19-22) Therefore, ENPP6 may act upstream of PHOS-
PHO1 to generate intravesicular PCho; however, the role of
ENPP6 in bone mineralization has yet to be investigated. This
study aims to characterize the skeletal phenotype of the global
ENPP6 KO mouse to give insight into its role in bone formation.
Materials and Methods
All chemical reagents were purchased from Sigma-Aldrich
(Gillingham, Dorset, UK) unless otherwise stated.
Animals
All experimental protocols were approved after review by the
University of Edinburgh Bioresearch and Veterinary Services
and maintained in accordance with UK Home Office guidelines
for the care and use of laboratory animals. Animals heterozygous
for a targeted deletion of exon1 of Enpp6 (Enpp6+/−) were
obtained from Taconic Biosciences (Rensselaer, NY, USA). The
animal model repository was generated through ES-cells of the
129/SvEv and C57BL/6 strain and subsequently maintained with
B6129F1mice. Colonies of WT (Enpp6+/+) and KO (Enpp6−/−) mice
were created by crossing heterozygous animals and subse-
quently maintained as separate colonies. Mice were housed in
standard polypropylene cages with ad libitum access to food
and water and environmental enrichment. The facility main-
tained a 12-hour light/dark cycle, and temperature was con-
trolled at 19 to 22C.
For skeletal phenotyping, female mice at 4 and 12 weeks of
age were used. Animals were culled using Schedule 1 methods,
and tissues were dissected for analysis. Tissues were processed
according to the protocols detailed below for downstream
analyses.
Primary osteoblast cell culture
Calvaria were dissected from entire litters of 3- to 5 day-old
Enpp6+/+mice, and primary osteoblasts extracted using standard
protocols.(23) Isolated cells were cultured in αMEM supplemen-
ted with 10% FBS and 50-μg/mL gentamicin (Invitrogen, Carls-
bad, CA, USA) at 37C in a humidified 5% CO2 atmosphere until
80% confluent, dissociated and seeded in 6-well plates at
100,000 cells per well. Once 80% confluence was reached, cells
were stimulated to assume an osteogenic phenotype, though
media supplementation with 50 μg/mL L-ascorbic acid and
1.5mM CaCl2 without an additional exogenous source of Pi as
previously described.(24)
Quantitative polymerase chain reaction
For RNA extraction from cells in culture, media was discarded,
and cells were washed three times in warm Hank’s balanced salt
solution. Cell monolayers were scraped in 1-mL cold Qiazol
(QIAGEN, Hilden, Germany). Samples were snap frozen in liquid
nitrogen and maintained at -70C before processing. For RNA
extraction from tissues, left femora were dissected, immediately
snap frozen in liquid nitrogen, and maintained at -70C before
tissue processing. Samples were homogenized in 1 mL of cold
Qiazol using an IKA T10 ULTRA-TURRAX tissue homogenizer
(IKA, Staufen, Germany).
RNA was isolated from both cell and tissue samples using the
RNeasy Mini kit according to manufacturer’s instructions (QIAGEN).
RNA concentrationwasmeasured using nanodrop spectrophotom-
etry (Thermo Fisher Scientific, Loughborough, UK), and purity
assessed using the 260:280-nm wavelength ratio. RNA was reverse
transcribed using SuperScript II (Thermo Fisher Scientific, Waltham,
MA, USA) as per the manufacturer’s instructions. Gene expression
was assayed using PrimerDesign PrecisionPlus Master Mix with pre-
mixedSYBRGreen (PrimerDesign, Chandler’s Ford, UK), using a Stra-
tagene Mx3000P real-time qPCR system (Agilent Technologies,
Cheadle,UK).Geneexpressiondatawerenormalized to18Sandana-
lyzed using the ΔΔCt method.(25) Oligonucleotide primers were
obtained from Sigma-Aldrich (Supplementary Table S1).
Immunohistochemistry and immunofluorescence
Right tibias were fixed in 4% paraformaldehyde (PFA) in PBS for
24 hours at 4C with gentle agitation and stored in 70% ethanol.
Tibias were decalcified in 10% EDTA, pH 7.4 for 14 to 21 days
under agitation, with the solution changed every 2 to 3 days.
Samples werewashed in PBS, sectioned in the sagittal plane, pro-
cessed to paraffin wax using a Leica ASP300S tissue processor
(Leica Biosystems, Wetzlar, Germany) and embedded in paraffin
blocks on themedial cut surface. Using a rotary microtome, 3-μm
sections were cut.
Deparaffinized slides were subject to enzyme-mediated anti-
gen retrieval through incubation in 1-mg/mL trypsin in 0.1%
CaCl2 at 37C for 30 minutes. Endogenous peroxidases were
quenched through incubation in 3% H2O2 in methanol for
30 minutes at room temperature. The Vectastain Elite ABC kit
(Vector Laboratories, Upper Heyford, UK) was used according
to the manufacturer’s instructions with a rabbit anti-ENPP6 pri-
mary antibody (ab224564; Abcam, Cambridge, UK) at a 1:20 dilu-
tion. Rabbit IgG was used at the same final concentration as the
primary antibody in negative isotype controls.
For immunofluorescence, slides were blocked in 10% normal
goat serum in 1% BSA for 1 hour at room temperature subse-
quent to antigen retrieval as above. Primary antibodies against
ENPP6 (as above), tissue nonspecific alkaline phosphatase
(TNAP; MAB2909; 1:500; R&D Systems, Minneapolis, MN, USA)
and PHOSPHO1 (HCA093; 1:500; Bio-Rad Laboratories, Deeside,
UK) were diluted in 1% BSA and incubated on sections at 4C
overnight in a humidified environment. Negative control sec-
tions were incubated in buffer only. Anti-rabbit AlexaFluor647
(A27040; Invitrogen), anti-rat AlexaFluor488 (A-11006; Invitro-
gen), and anti-human AlexaFluor594 (A-11014; Invitrogen) sec-
ondary antibodies were used at 2 μg/mL and incubated for
1 hour at room temperature. Slides were counterstained in
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Hoechst andmounted in ProLong Gold (Thermo Fisher Scientific,
UK). Images were acquired using an LSM 880 laser scanning con-
focal microscope with a 63× oil-immersion objective lens (Zeiss,
Cambridge, UK).
Micro-computed tomography
For μCT, left tibias and phantom calibration standards were
embedded in 1% agarose and scanned using a SkyScan 1172 desk-
top micro-CT (Bruker, Kontich, Belgium) through 360 degrees in
steps of 0.280 degrees with two-frame averaging. A voxel resolu-
tion of 6.03 μm was obtained with the following settings; 54 kV
source voltage, 185 μA source current, and an exposure time of
1767 ms, with a 0.5 mm aluminium filter. Data were reconstructed
using NRecon v1.6.9 (Bruker). Reconstruction thresholding was
optimized to encapsulate the target image, defined by attenuation
coefficients of 0.005 to 0.100. Ring artifact correction was set to
5 and a beam-hardening correctionof 20%was applied. Consistent
settings were used for all samples.
After reconstruction, CtAn v1.16.4 (Bruker) was used to analyze
metaphyseal trabecular bone parameters as previously
described.(26) A 250-slice subset of metaphyseal trabecular bone
was used for analysis, using the base of the growth plate as a stan-
dard reference point. Whole-bone cortical analysis was performed
using the BoneJ image analysis package(27) for Fiji.(28) Recon-
structed scans of individual bones were first consistently oriented
using themoments of inertia function, the trabecular bone and fib-
ula were removed from the images, and the data set cropped 10%
to 90% or 15% to 90% of total bone length in 12- and 4-week-old
bones, respectively, to exclude the epiphysis and proximal and dis-
tal growth plates. Cortical bone parameters were then analyzed
using the BoneJ slice geometry function. Data were processed
and visualized using R.(29) BMD was calculated based on known-
density hydroxyapatite phantoms imagedunder identical conditions
as experimental samples, and appropriate calibration performed
against attenuation coefficients in both CtAn and BoneJ.
Back-scattered scanning electron microscopy
Right humeri were fixed in 2.5% PFA; 2.5% glutaraldehyde in
0.1M sodium cacodylate overnight at 4C with gentle agitation.
Samples were bisected, dehydrated in an ethanol series, and
subjected to CO2 critical point drying using a Polaron E3100
dryer (Quorum Technologies, East Sussex, UK). Humeri were
embedded in an epoxy resin block, ground using 2500 grit sili-
con carbide paper with water until plane, and polished on a
Metaserv polisher (Buehler, Lake Bluff, IL, USA) using 0.3-μm alu-
minium oxide powder before a thin carbon coat was applied to
the surface. The block was mounted on a 25-mm stub and exam-
ined under back-scattered SEM (BSE-SEM) using a Sigma HD VP
microscope (Zeiss) fitted with a four-quadrant solid-state angle
selective backscatter detector and operating at 15 keV, at a
working distance of 7 mm and aperture size of 30 μm. Energy-
dispersive X-ray spectroscopy (EDS) was performed using the
AZtecEnergy system (Oxford Instruments, Abingdon, UK).
Three-point bending
Left humeri were cleaned of soft tissue, frozen in distilled water
and stored at -20C. Three-point bending was carried out using
a Lloyd LRX5 materials testing machine (Lloyd Instruments, Bog-
nor Regis, UK) fitted with a 100-N load cell. The span was fixed at
10 mm and bones loaded with a cross-head speed of 1 mm/min
until failure as previously described.(10)
Histology and static histomorphometrics
We stained 3-μm sections of the right tibia (prepared as above) with
H&E and Goldner’s trichrome using standard protocols. For tartrate-
resistantacidphosphatae(TRAP)staining,70-mgnaptholAS-TRphos-
phatewasdissolved in250-μL N-Ndimethyl formamideandaddedto
50 mLof2.3-mg/mLsodiumtartratedihydrate;1.4 mg/mLfastredsalt
TR solution in 0.2M sodium acetate buffer (pH 5.2). Deparaffinized
slideswere incubated in staining solution at 37C for 1 hour, counter-
stained in Meyer’s hematoxylin, andmounted in aqueous mounting
medium (Vector Laboratories). Slides were imaged using a
NanoZoomer-XR slide scanning system (Hamamatsu Photonics,
HamamatsuCity, Shizuoka, Japan). Static histomorphometrywasper-
formed using the BIOQUANT OSTEO software package (BIOQUANT
Image Analysis Corp, Nashville, TN, USA) as per the manufacturer’s
instructions and following ASBMR’s bone histomorphometry
guidelines.(30)
Osmium bone marrow fat analysis
Following μCT analysis at 12 weeks, bones were removed from 1%
agarose andwashed in Sorensen’s phosphate buffer (81mMKH2PO4,
19mM Na2HPO4  7H2O, pH 7.4) prior to decalcification. Tibia were
decalcified in 14% EDTA for 2 weeks at 4C, washed in Sorensen’s
phosphate buffer and stained with 1% osmium tetroxide solution
(1% w/v; diluted 1:1 in Sorensen’s phosphate buffer; Agar Scientific,
Stansted, Essex, UK) for 48 hours at room temperature, washed,
and stored in Sorensen’s phosphate buffer at 4C. Stained tibiaswere
embedded in 1% agarose and scanned using a Skyscan 1172 desk-
top micro-CT (Bruker) as previously described.(31,32) The data were
reconstructed using Skyscan software NRecon v1.6.9.4 (Bruker). Volu-
metric analysis was performed using CTAn v1.13.5.1 (Bruker).
Statistical analysis
Data are expressed as mean  SD of at least four replicates per
experiment. Sample size for each analysis is provided in the rele-
vant figure legends. Significance testing was performed using
either R(29) or SPSS (IBM, Armonk, NY, USA) after appropriate test-
ing for normality and homogeneity of variance. Statistical signif-
icance was defined by a p value of <0.05.
Results
ENPP6 is expressed in mature osteoblasts and is
upregulated during mineralization in vitro
The localization of ENPP6was first investigated in Enpp6+/+ tissue
to ensure expression at the mineralizing front. Immunohisto-
chemical staining in 4-week WT tibias revealed expression local-
ized strongly to osteoblasts at mineralizing surfaces in both
trabecular and cortical bone (Fig. 1A; black arrowheads). Expres-
sion was also noted in early osteocytes at both sites (Fig. 1A;
white arrowheads). Immunofluorescence staining with confocal
microscopy revealed expression of ENPP6 in mature osteoblasts
at trabecular and cortical sites, which also exhibited strong TNAP
and PHOSPHO1 colocalization (Fig. 1B). Surprisingly, ENPP6 also
showed strong nuclear (Fig. 1B; white arrowheads), along with
cytoplasmic (Fig. 1B; white arrows) localization. Furthermore, pri-
mary osteoblasts exhibited a significant upregulation of Enpp6
over a mineralizing time course in culture, along with both Phos-
pho1 and Alpl (p > 0.001; Fig. 1C,D).
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Fig 1. Ectonucleotide pyrophosphatase/phosphodiesterase 6 (ENPP6) is expressed at sites of bone formation and is upregulated during mineralization
in vitro. (A) Immunohistochemistry using an anti-ENPP6 primary antibody in 4-week tibias shows expression in cells at mineralizing surfaces in both tra-
becular and cortical bone, including osteoblasts (black arrowheads) and early osteocytes (white arrowheads). Scale bars = 50 μm. (B) Immunofluoresence
staining for ENPP6 in Enpp6+/+ 4-week tibias shows colocalization with mineralizing markers tissue nonspecific alkaline phosphatase (TNAP) and orphan
phosphatase 1 (PHOSPHO1) in both trabecular and cortical bone. ENPP6 staining is evident in both nuclei (white arrowheads) and the cytoplasm (white
arrows). Scale bar = 50 μm. (C) Alizarin red staining in primary osteoblasts showingmineralized nodules generated over a time course. (D) Gene expression
analysis in primary osteoblasts shows upregulation of Enpp6 over a mineralizing time course along with other mineralization markers including Phospho1
and Alpl. n = 3 (day 0); n = 4 (day 7–day 21). **p > 0.01; ***p > 0.001.
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Fig 2. Micro-computed tomography analysis of trabecular bone in Enpp6WT and KO tibias at 4 and 12 weeks of age shows hypomineralization of the trabecular
and cortical bone compartment in 4-week tibias and alteration of geometry. (A–G) Trabecular bone parameters measured from a 250-slice volume distal to the
growth plate. Data represent mean  SD. *p > 0.05. (H–M) Whole-bone cortical analysis at 4 weeks (H–J) and 12 weeks (K–M) from 15% and 10%, respectively,
to 90% tibial length. Solid lines represent the mean  SD. Individual data points are plotted within each % length bracket. The results of statistical significance
testing between genotypes performed using multiple t tests with Bonferroni correction for multiple comparisons are reported at each length bracket using col-
ored bars. BV/TV = Bone volume/total volume. n = 4-week Enpp6−/− 4; 4-week Enpp6+/+ 5; 12-week Enpp6−/− 5; Enpp6+/+ 4.
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Ablation of Enpp6 results in transient hypomineralization
of trabecular and cortical bone and delayed propagation
of mineralization foci
To elucidate differences in bone structure and/or mineral density
in the absence of functional ENPP6, μCT of the left tibia was
performed. The skeletal phenotype was hypothesized to recover
over time in a similar manner to the Phospho1−/− phenotype(9);
therefore, animals were investigated at both 4 weeks and
12 weeks of age.
At 4 weeks of age, trabecular bone at theproximal tibiawas found
to be significantly hypomineralized in Enpp6−/− compared with con-
trols (p < 0.05; Fig. 2A). The structural model index (SMI) was also
found to be significantly higher in Enpp6−/− samples (p < 0.05;
Fig. 2B), with all other structural parameters showing no difference
between genotypes (Fig. 2C–G). However, trabecular hypominerali-
zation had recovered by 12 weeks of age, and SMI was similarly cor-
rected (Fig. 2A,B). The remaining structural parameters remained
consistent between genotypes at 12 weeks (Fig. 2C–G).
Whole-bone cortical μCT analysis was conducted to investigate
whether the hypomineralization observed in trabecular bone in
young animals extended to the cortical bone compartment.
Four-week and 12-week tibias were analyzed from 15% and 10%
total length, respectively, to 90% total length to exclude the prox-
imal and distal metaphyses and growth plates. Cortical bone in
4-week Enpp6−/− animals was found to be hypomineralized with
respect to controls in proximal regions (p < 0.05) but were miner-
alized normally more distally (Fig. 2H). Hypomineralized regions
coincidedwith reductions in cross-sectional area andmean cortical
thickness; however, both were also significantly lower in other
regions at the midshaft and more distally (Fig. 2I,J). Moments of
inertia about the major and minor axes were also quantified to
measure changes in cortical geometry. Imax and Imin were found
to be significantly reduced in some midshaft-distal regions
(0.01 < p < 0.05; Supplementary Fig. S1A,B).
The hypomineralized phenotype was found to be corrected in
Enpp6−/− proximal cortical bone at 12 weeks. Surprisingly, a small
significantly hypermineralized area was found at the midshaft in
Enpp6−/− samples (p < 0.05; Fig. 2K). Furthermore, generalized
increases throughout the length of 12-week Enpp6−/− tibias were
observed in cross-sectional area, mean cortical thickness, and Imin
and Imax (0.001 < p < 0.05; Fig. 2L,M; Supplementary Fig. S1C,D).
Hypomineralization of both cortical and trabecular bone in
4-week samples was confirmed by BSE-SEM. In trabecular bone,
large areas of retained calcified cartilage were evident in
Enpp6−/− animals compared with the controls (Fig. 3A). Further-
more, several regions exhibited small (~1 μm) electron-dense
particles embedded within developing trabeculae, which were
not present in control samples (Fig. 3A; white arrowheads). Parti-
cles progressively aggregated to fuse with the surrounding tis-
sue (Fig. 3A; white arrow). The elemental composition of these
particles was investigated by EDS revealing enrichment in cal-
cium, phosphorus, oxygen, and carbon (Fig. 3B), with some other
Fig 3. Back-scattered SEM of Enpp6+/+ and Enpp6−/− 4-week humeri
showing hypomineralization within both trabecular and cortical bone
compartments. (A) Trabecular bone exhibits retention of large areas of
calcified cartilage in Enpp6−/− animals and a failure of mineralization foci
to propagate (white arrowheads). Foci fused with the surrounding devel-
oping trabecula (white arrow). (B) Energy-dispersive spectroscopy ofmin-
eralization foci and surrounding tissue taken at the numbered positions.
Spectra show enrichment of P, Ca, O, and C confirming electron-dense
particles represent mineralization foci. (C) Cortical bone at the endosteal
surface also exhibits hypomineralization in Enpp6−/− bones (white arrow-
heads). P = Phosphorous; Ca = Calcium; O = Oxygen; C = Carbon. Scale
bars = 25 μm.
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Fig 4. Mechanical testing and static histomorphometry show alteredmechanical properties and hyperosteoidosis, without a change in bone cell activity.
(A–C) three-point bending in KO and WT humeri showing significantly altered mechanical properties of Enpp6−/− bones in (A) bone length; (B) maximum
load to failure; and (C) work to maximum load. (D,E) Static histomorphometry within the trabecular compartment of 4- and 12-week tibias shows hyper-
osteoidosis in young animals that subsequently recovers in older animals. (F–H) No differences in either age group were evident between genotypes in
either normalized osteoblast or osteoclast number, or osteoclast surface. Data represent mean  SD. OV/BV = osteoid volume/bone volume; OS/BS =
osteoid surface/bone surface; N.Ob/BS = number of osteoblasts/bone surface; N.Oc/BS = number of osteoclasts/bone surface; Oc.S/BS = osteoclast sur-
face/bone surface; n = 4-week Enpp6−/− 4; 4-week Enpp6+/+ 4; 12-week Enpp6−/− 4; Enpp6+/+ 5. *p > 0.05; **p > 0.01.
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trace elements including sodium and magnesium (data not
shown). Particles were generally similar in composition to the
surrounding mineralized tissue (Fig. 3B). Therefore, particles
likely represent mineralization foci that have failed to propagate
in the absence of ENPP6. Generalized hypomineralization of
diaphyseal cortical bone at the endosteal surface was also appar-
ent in Enpp6−/− animals (Fig. 3C; white arrowheads).
Enpp6−/− bones exhibit altered material properties but no
change in bone cell activity
Three-point bending was performed to investigate whether
observed changes between genotypes influences bone material
properties. Both 4- and 12-week Enpp6−/− humeri were significantly
longer than WT counterparts (p < 0.01 and p < 0.05, respectively;
Fig. 4A), although the average difference between genotypes was
reduced in the older animals. Similarly, maximum load to failure
was significantly higher at both 4 and 12 weeks (p < 0.01,
p < 0.05; Fig. 4B) as was work to maximum load (p < 0.05; Fig. 4C).
Static histomorphometry within the trabecular compartment
of the tibia was performed to determine whether hypominerali-
zation resulted from altered bone cell activity. Significant
increases in osteoid volume (p > 0.05) and osteoid surface
(p > 0.05) were observed in 4-week Enpp6−/− animals compared
with controls, which had normalized by 12 weeks of age (Fig. 4D,
E). This was not accompanied by an increase in osteoblast num-
ber (Fig. 4F). No differences were detected in either osteoclast
number or surface between genotypes in either age group
(Fig. 4G,H). Accumulation of large osteoid seams was evident in
4-week Enpp6−/− tissue compared with controls, both in trabec-
ular and cortical bone (Fig. 4I; white arrowheads), whereas differ-
ences had normalized by 12 weeks of age (Fig. 4I).
Altered skeletal mineralization is not accompanied by
changes in bone marrow adipose tissue volume
As ENPP6 has also been implicated in fat metabolism, we inves-
tigated bone marrow adipose tissue (BMAT) volume in these
mice.(33) Recent evidence implicates a link between bone and
energy metabolism, and we therefore hypothesized that abla-
tion of Enpp6 and induced hypomineralization would effect
changes in BMAT.(1) Osmium tetroxide staining and μCT analysis
of 12-week WT and Enpp6−/− tibia revealed that there was no
alteration of BMAT volume despite hypomineralization in
Fig 5. Quantitative bonemarrow fat analysis shows no significant differences in the volume of bonemarrow adipose tissue normalized to tissue volumewithin
either the proximal or distal compartments of the tibia between genotypes in 12-week animals. BMAT volume is expressed as% volumenormalized tomedullary
cavity volume. The proximalmedullary compartment was defined from the growth plate (G/P) to the tibiofibular joint (T/FJ) and distal compartment as from the
T/FJ to the distal extremity of the medullary cavity. BMAT/TV = bone marrow adipose tissue/total volume. Data represent mean  SD. n = 4 WT; 5 Enpp6−/−.
n = Enpp6−/− 5; Enpp6+/+ 4.
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trabecular and cortical bone (Fig. 5). These analyses were not
attempted in 4-week bones as BMAT is not yet evident in these
young animals.
Discussion
This study is the first to characterize the skeletal phenotype of
the Enpp6−/− mouse, revealing transient hypomineralization in
young animals compared with controls, accompanied by
impaired structural and functional properties and a failure of
mineralization foci in the trabecular compartment to propagate
and fuse. To date, the function of ENPP6 during bonemineraliza-
tion has not received much attention; however, a few studies
have provided incidental evidence to suggest it has a role to
play. Upregulation of Enpp6 expression has been found during
osteogenesis, and therefore active bone mineralization in
diverse contexts, including osseointegration of dental
implants(34) and enhanced bone modeling in response to a com-
bination of sclerostin-neutralizing antibody treatment and
in vivo mechanical loading.(35) Consistent with these observa-
tions, Enpp6 expression is lower in bones of the Hyp mouse at
12 days of age (a murine homolog of X-linked hypophosphate-
mic rickets) comparedwith controls.(36) Downregulationwas also
observed in a CRISPR Cas9-engineered osteogenesis imperfecta
type V mouse model resulting in severe skeletal and mineraliza-
tion defects in late-stage mouse embryos, potentially caused by
a deficiency in osteoblast differentiation.(37) Furthermore, over-
expression of Runx2 in mouse limb bud cultures leads to a more
than threefold increase in Enpp6, which is well-correlated with
the upregulation observed in establishedmineralization markers
including Phospho1 and Bglap2, among others.(38)
Therefore, the expression of the Enpp6 gene in osteogenic
cells appears to be correlated with mineralization. Our observa-
tions agree with those from the literature, confirming ENPP6
localization to mineralizing cells including osteoblasts and early
osteocytes. Furthermore, immunofluorescence staining co-
expresses with other mineralization markers such as TNAP and
PHOSPHO1. Nuclear in addition to cytoplasmic localization of
ENPP6 observed here may indicate that ENPP6 plays other roles
in the cell in addition to its potential function in mineralization.
The targeting mechanisms regulating ENPP6 are currently
unclear, and previous work has shown distinct localizations of
the protein in oligodendrocytes during brain development, for
example.(22) Taken together with in vitro results reported here
showing an increase of Enpp6 expression in primary calvarial
osteoblasts over a mineralizing time course, these data provide
evidence of a role for ENPP6 during bone formation.
The specific function of ENPP6 remains unclear, however,
given its established lysophospholipase C activity.(19-21) The sim-
ilarities of the phenotype described here to that of the Phos-
pho1−/− mouse are clear. As discussed above, ablation of
PHOSPHO1 in mice induces hypomineralization in young ani-
mals, resulting in rickets/osteomalacia and biomechanical defi-
ciency.(9-11) Here we report that 4-week Enpp6−/− tibias exhibit
hypomineralized trabecular bone compared with controls, along
with a significant increase in SMI indicating a change in trabecu-
lar geometry. Whole-bone cortical analysis revealed the same
trend with significantly reduced mineral density in proximal
regions (ie, young tissue) and decreased mean cortical thickness,
cross-sectional area, and Imin at these and midshaft sites. At
12 weeks these differences not only recovered but inmany areas
along the length of the tibia exhibited significant increases in the
KO compared with the WT, potentially indicating a compensa-
tory response. Interestingly, this was not accompanied by any
changes in expression of mineralization-associated genes,
including Alpl and Phospho1, which were upregulated on aver-
age at 12 weeks in Enpp6−/− bones but did not reach the level
of statistical significance (Supplementary Fig. S2). Furthermore,
we observed hyperosteoidosis in young animals that subse-
quently recovered (Fig. 4). The pattern of staining observed here
is unusual, with some hypomineralized tissue lying deep to the
bone surface. Although this pattern is curious, this correlates well
with the BSE-SEM data, revealing a failure of mineralization foci
to propagate within some trabeculae in Enpp6-null 4-week ani-
mals. This may also correspond to the patchy osteomalacia pre-
viously described in mice lacking PHOSPHO1.(11) We also report
significant increases in maximum load to failure and work to
maximum load in 4- and 12-week Enpp6−/− humeri. Given the
evident bone hypomineralization, this is a surprising finding
but may represent an increased elasticity and plastic deforma-
tion under load as has also been shown in Phospho1−/− bones.(10)
It is also possible that alteredmaterial properties are a product of
the structural changes in, for example, cortical thickness as
shown here; further work is required to explicitly define this
relationship.
The Enpp6−/− phenotype appears to represent an attenuated
form of that evident in Phospho1−/− animals which recovers over
time. Our data are consistent with the hypothesis that ENPP6
functions upstream of PHOSPHO1 to generate PCho and thereby
facilitate generation of Pi for bone mineralization at the early
stages of bone development. Several authors proposed this rela-
tionship, implicating the action of an as-yet unidentified enzyme
with phospholipase A2 activity and ENPP6 in combination
upstream of PHOSPHO1 in scavenging Pi from the MV mem-
brane.(3,16) Although a more direct pathway might be to gener-
ate PCho by hydrolysis of phosphatidylcholine (PC) through an
enzyme with phospholipase C (PLC) activity, PC-specific PLCs
have yet to be found in mineralizing mammalian cells.(17) During
mineralization, the lipid composition of the MV membrane
changes dramatically, showing the degradation of phospho-
lipids such as PC and phosphatidylethanolamine (PE) and high
concentrations of lysophospholipid breakdown products.(39-42)
These studies establish that phospholipases, including those
with lysophospholipase C activity such as ENPP6, are active
within the MV and may function to provide substrates for PHOS-
PHO1 and other phosphatases. This mechanism would allow the
intravesicular accumulation of Pi within a locally protected
chemical environment, but also may function to progressively
destabilize the vesicle membrane and facilitate release of its
cargo.
The mineralization defects observed here in 4-week Enpp6−/−
animals may represent disruption of this mechanism, resulting in
delayed phosphate accumulation and mineral nucleation. How-
ever, the milder nature of this phenotype (compared with Phos-
pho1−/− mice) and its recovery by 12 weeks of age suggests
other concurrent mechanisms are at play, but that ENPP6 plays
a significant role during early postnatal bone development.
PHOSPHO1 has been shown to hydrolyze PEA in addition to
PCho.(14) Ablation of ENPP6 and resulting loss of PCho accumula-
tion may, therefore, only represent one pool of the substrate
available for PHOSPHO1-mediated Pi generation. The mecha-
nism through which PEA may be generated inside MVs has yet
to be established, however. In addition, sphingomyelin phos-
phodiesterase 3 (SMPD3; Smpd3) catalyzes hydrolysis of the
phospholipid sphingomyelin to ceramide and PCho, and has also
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been implicated in this process.(43) In a similar manner to PC and
PE, sphingomyelin is also enrichedwithin theMVmembrane and
undergoes degradation during mineralization.(17,39-42) Further-
more, mutation of Smpd3, as in the fragilitas ossium (fro/fro)
mouse model, causes severe skeletal defects, phenocopying
noncollagenous osteogenesis imperfecta and resulting in bone
hypomineralization and rickets/osteomlacia.(44,45) Although both
ENPP6 and SMPD3 may generate PCho upstream of PHOSPHO1,
it is also likely that this mechanism works synergistically with the
established function of TNAP. The critical cooperation between
PHOSPHO1 and TNAP can be seen dramatically in the double
KO Phospho1−/−;Alpl−/− mouse, which exhibits a complete lack
of skeletal mineralization and perinatal lethality.(46)
This research has for the first time highlighted a significant
role for ENPP6 in bone formation and mineralization. These data
provide a promising avenue of investigation; further research is
required to confirm ENPP6 activity as part of the PHOSPHO1
pathway during MV-mediated biomineralization.
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